{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:20:28Z","timestamp":1791350428818,"version":"4.3.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jneuroim.2026.578928","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:49:56Z","timestamp":1775260196000},"page":"578928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tracking the invisible: Impact of disease-modifying therapies on serum neurofilament light chain and clinical outcomes in treatment-na\u00efve multiple sclerosis"],"prefix":"10.1016","volume":"417","author":[{"given":"Eman M.","family":"Khedr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourelhoda A.","family":"Haridy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Bahey","family":"El-Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelwarith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.578928_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp-2025-335831","article-title":"Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis","volume":"96","author":"Abdelhak","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000885","article-title":"Serum neurofilament light chain: no clear relation to cognition and neuropsychiatric symptoms in stable MS","volume":"7","author":"Aktas","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104163","article-title":"Relationship of coping strategies with mood symptoms, disease related characteristics and demographic variables in patients with multiple sclerosis: a systematic review study","volume":"67","author":"Bahmani","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0020","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0025","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0040","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/NDT.S173280","article-title":"Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study","volume":"14","author":"Cai","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578928_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0050","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S56.008","article-title":"Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of b cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study (s56.008)","volume":"92","author":"Cross","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0065","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s00415-022-11468-2","article-title":"Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological\u2013serological correlative study","volume":"270","author":"Dietmann","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0075","author":"Egyptian Health Council E"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0090","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578928_bb0095","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","volume":"2013","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00415-025-13231-9","article-title":"Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)","volume":"272","author":"Fung","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","article-title":"Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review","volume":"26","author":"Gasim","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0110","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s40120-023-00535-z","article-title":"Neurofilament light chain in adult and pediatric multiple sclerosis: a promising biomarker to better characterize disease activity and personalize MS treatment","volume":"12","author":"Ghezzi","year":"2023","journal-title":"Neurology and Therapy"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578928_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104800","article-title":"Current and future trends in multiple sclerosis management: near east perspective","volume":"76","author":"Hatem","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1380\u201390","key":"10.1016\/j.jneuroim.2026.578928_bb0140","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0150","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/13524585211017013","article-title":"The timed 25-foot walk in a large cohort of multiple sclerosis patients","volume":"28","author":"Kalinowski","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0160","first-page":"77","article-title":"Hand strength and dexterity","volume":"25","author":"Kellor","year":"1971","journal-title":"Am. J. Occup. Ther."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s41983-025-01050-8","article-title":"Baseline serum neurofilament light chain: a diagnostic biomarker in drug-na\u00efve multiple sclerosis patients","volume":"61","author":"Khedr","year":"2025","journal-title":"Egypt. J. Neurol. Psychiatr. Neurosurg."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106286","article-title":"A real-world data of serum neurofilament light chain in a large cohort of egyptian multiple sclerosis patients: hospital-based study","volume":"94","author":"Khedr","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0175","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/ene.13339","article-title":"Patient-reported outcomes in multiple sclerosis: a systematic comparison of available measures","volume":"24","author":"Khurana","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0180","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0185","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0190","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jneuroim.2026.578928_bb0195","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/13524585251335521","article-title":"Change in serum neurofilament light chain and glial fibrillary acidic protein levels with high-efficacy and low-efficacy early therapy in multiple sclerosis","volume":"31","author":"Madill","year":"2025","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine hole peg test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occup. Ther. J. Res."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0210","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0215","first-page":"480","article-title":"Anxiety and depression as comorbidities of multiple sclerosis","volume":"33","author":"Musta\u010d","year":"2021","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0220","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0225","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0230","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/13548506.2016.1274043","article-title":"The first year after diagnosis: psychological impact on people with multiple sclerosis","volume":"22","author":"Possa","year":"2017","journal-title":"Psychol. Health Med."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0235","article-title":"CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.","volume":"7","author":"Reyes","year":"2020","journal-title":"Neurology: Neuroimmunology & Neuroinflammation."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0240","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneurol.2013.146","article-title":"Defining and scoring response to IFN-\u03b2 in multiple sclerosis","volume":"9","author":"Sormani","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0245","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x202010428","article-title":"Depression and anxiety disorders in patients with multiple sclerosis: association with neurodegeneration and neurofilaments","volume":"54","author":"Tauil","year":"2021","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the neurologist\u2019s troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jneuroim.2026.578928_bb0255","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0260","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fneur.2019.00338","article-title":"Neurofilament light chain as a biomarker in multiple sclerosis","volume":"10","author":"Varhaug","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578928_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:54:03Z","timestamp":1784552043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"alternative-id":["S0165572826000767"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578928","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tracking the invisible: Impact of disease-modifying therapies on serum neurofilament light chain and clinical outcomes in treatment-na\u00efve multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578928"}}